Bone marrow mononuclear cell therapy in experimental allergic asthma: Intratracheal versus intravenous administration  by Abreu, Soraia C. et al.
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We  hypothesized  that  the  route  of administration  would  impact  the  beneﬁcial  effects  of  bone  marrow-
derived  mononuclear  cell  (BMDMC)  therapy  on the  remodelling  process  of  asthma.  C57BL/6  mice  were
randomly  assigned  to two main  groups.  In the  OVA  group,  mice  were  sensitized  and challenged  with
ovalbumin,  while  the  control  group  received  saline  using  the  same  protocol.  Twenty-four  hours  before  the
ﬁrst challenge,  control  and  OVA  animals  were  further  randomized  into  three  subgroups  to receive saline
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rowth factor
(SAL), BMDMCs  intravenously  (2  × 10 ),  or BMDMCs  intratracheally  (2 × 10 ). The  following  changes
were  induced  by  BMDMC  therapy  in OVA  mice  regardless  of administration  route:  reduction  in resistive
and  viscoelastic  pressures,  static  elastance,  eosinophil  inﬁltration,  collagen  ﬁbre  content  in  airways  and
lung  parenchyma;  and  reduction  in the  levels  of  interleukin  (IL)-4,  IL-13,  transforming  growth  factor-
and  vascular  endothelial  growth  factor.  In conclusion,  BMDMC  modulated  inﬂammatory  and  remodelling
processes  regardless  of  administration  route  in this  experimental  model  of allergic  asthma.
© 2012 Elsevier B.V. Open access under the Elsevier OA license.. Introduction
Intravenous administration of bone marrow-derived mono-
uclear cells (BMDMCs) attenuates both inﬂammatory and
emodelling responses in experimental allergic asthma (Abreu
t al., 2011a).  This improvement was observed despite a very low
ngraftment rate, possibly as a result of immune response modu-
ation promoted by the administered cells through the release of
ytokines and growth factors (Abreu et al., 2011a).
Intravenous infusion is often used in preclinical studies for
he delivery of various cell types, including mesenchymal stem
ells (MSCs) (Bonﬁeld et al., 2010; Nemeth et al., 2010; Goodwin
t al., 2011) and BMDMCs (Abreu et al., 2011a).  This is because the
ntravenous route provides broad biodistribution and easy admin-
stration. However, only a small number of cells are delivered to
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Open access under the Elsevier OA license.the damaged area using this route (Schrepfer et al., 2007). Mean-
while, a previous study with cardiosphere-derived cells found that
the beneﬁts of cell administration were associated with injection
route and with the number of cells delivered with each route at the
site of injury (Bonios et al., 2011).
We hypothesize that intratracheal (IT) delivery of BMDMCs may
be more effective than intravenous (IV) administration to reduce
the inﬂammatory and remodelling processes and promote air-
way epithelial repair in experimental allergic asthma. To test this
hypothesis, lung histology ﬁndings, collagen ﬁbre content in the
airway and alveolar septa, levels of cytokines and growth factors in
lung tissue, and lung mechanics were analyzed following IT and IV
administration of BMDMCs in a murine model of allergic asthma.
2. Materials and methods
This study was approved by the Ethics Committee of the Health
Sciences Centre, Federal University of Rio de Janeiro. All animals
received humane care in compliance with the “Principles of Labo-
ratory Animal Care” formulated by the National Society for Medical
Research and the U.S. National Research Council “Guide for the Care
and Use of Laboratory Animals”.
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.1. Extraction and characterization of bone marrow-derived
ononuclear cells
Bone marrow cells were extracted from male C57BL/6 mice
weight 20–25 g, n = 10) and administered on the day of collec-
ion. Alternatively, BMDMCs were obtained from GFP+ male mice
weight 20–25 g, n = 5) and administered to C57BL/6 female mice
o evaluate the degree of pulmonary GFP+ cell engraftment. Brieﬂy,
one marrow cells were aspirated from the femur and tibia by
ushing the bone marrow cavity with Dulbecco’s modiﬁed Eagle’s
edium (DMEM) (Life Technologies, Grand Island, NY, USA). After
 homogeneous cell suspension was achieved, cells were cen-
rifuged (400 × g for 10 min), re-suspended in DMEM and added
o Ficoll-Hypaque (Histopaque 1083, Sigma Chemical Co., St. Louis,
O,  USA), and again centrifuged and re-suspended in phosphate-
uffered saline (PBS). Cells were counted in a Neubauer chamber
ith Trypan Blue for the evaluation of viability. For the admin-
stration of saline or BMDMCs, mice were anaesthetized with
evoﬂurane, the jugular vein or the trachea of each mouse was
issected, and cells were slowly injected. A small aliquot of mono-
uclear cells was used for immunophenotypic characterization of
he injected cell population. Cell characterization was performed by
ow cytometry using antibodies against CD45 (leukocytes), CD34
haematopoietic precursors), CD3, CD8, and CD4 (T lymphocytes),
D19 (B lymphocytes), CD14 (monocytes), CD11b, CD29 and CD45
mesenchymal stem cells), all from BD Biosciences, USA.
.2. Animal preparation and experimental protocol
Thirty-six female C57BL/6 mice (20–25 g) were randomly
ssigned to two groups. In the OVA group, mice were immunized
sing an adjuvant-free protocol by intraperitoneal injection of ster-
le ovalbumin (OVA, 10 g OVA in 100 l saline) on 7 alternate days.
orty days after the start of sensitization, 20 g of OVA in 20 l
aline was instilled intratracheally. This procedure was  performed 3
imes with 3-day intervals between applications (Xisto et al., 2005).
he control group (C) received saline using the same protocol. The
 and OVA groups were further randomized to receive saline solu-
ion (0.9% NaCl, 50 l, SAL) or BMDMCs (2 × 106 in 50 l, CELL),
ntravenously (through the left jugular vein) or intratracheally, 24 h
efore the ﬁrst challenge (Fig. 1).
.3. Mechanical parameters
Twenty-four hours after the last intratracheal challenge with
aline or OVA, animals were sedated (diazepam 1 mg ip),
naesthetized (thiopental sodium 20 mg/kg ip), tracheotomized,
aralyzed (vecuronium bromide, 0.005 mg/kg iv), and ventilated
ith a constant ﬂow ventilator (Samay VR15; Universidad de la
epublica, Montevideo, Uruguay) set to the following parame-
ers: frequency 100 breaths/min, tidal volume (VT) 0.2 mL,  and
raction of inspired oxygen (FiO2) 0.21. The anterior chest wall
as surgically removed and a positive end-expiratory pressure of
 cmH2O applied. Airﬂow and tracheal pressure (Ptr) were mea-
ured (Burburan et al., 2007). Lung mechanics were analyzed by
he end-inﬂation occlusion method (Bates et al., 1988). In an open
hest preparation, Ptr reﬂects transpulmonary pressure (PL). Brieﬂy,
fter end-inspiratory occlusion, there is an initial rapid decline in PL
P1) from the preocclusion value down to an inﬂection point (Pi),
ollowed by a slow pressure decay (P2), until a plateau is reached.
his plateau corresponds to the elastic recoil pressure of the lung
Pel). P1 selectively reﬂects the pressure used to overcome airway
esistance. P2 reproduces the pressure spent by stress relaxation,
r viscoelastic properties of the lung, as well as a minor contri-
ution of pendelluft. Static lung elastance (Est) was determined by
ividing Pel by VT. Lung mechanics measurements were obtained Neurobiology 185 (2013) 615– 624
10 times in each animal. All data were analyzed using ANADAT
software (RHT-InfoData, Inc., Montreal, Quebec, Canada).
2.4. Lung histology
Laparotomy was  performed immediately after determination of
lung mechanics and heparin (1000 IU) was injected into the vena
cava. The trachea was clamped at end expiration and the abdominal
aorta and vena cava were sectioned, producing massive haemorr-
hage and rapid terminal bleeding. The left lung of each animal was
then removed, ﬂash-frozen by immersion in liquid nitrogen, ﬁxed
with Carnoy solution, and embedded in parafﬁn. Four-micrometre-
thick slices were cut and stained with haematoxylin–eosin.
Lung histology analysis was  performed with an integrating eye-
piece with a coherent system consisting of a grid with 100 points
and 50 lines (known length) coupled to a conventional light micro-
scope (Olympus BX51, Olympus Latin America-Inc., Brazil). The
volume fraction of collapsed and normal pulmonary areas, mag-
nitude of bronchoconstriction, and number of mononuclear (MN)
and polymorphonuclear cells (PMN, neutrophils and eosinophils)
in lung tissue were determined by the point-counting technique
(Weibel, 1990; Hsia et al., 2010) across 10 random, non-coincident
microscopic ﬁelds (Xisto et al., 2005; Burburan et al., 2007).
Collagen (Picrosirius-polarization method) and elastic ﬁbres
(Weigert’s resorcin fuchsin method with oxidation) were quanti-
ﬁed in airways and alveolar septa using Image-Pro Plus 6.0 (Xisto
et al., 2005; Antunes et al., 2009, 2010).
2.5. Transmission electron microscopy
Three 2 mm × 2 mm × 2 mm fragments were cut from three dif-
ferent segments of the right lung and ﬁxed [2.5% glutaraldehyde
and phosphate buffer 0.1 M (pH = 7.4)] for electron microscopy
analysis (JEOL 1010 Transmission Electron Microscope, Tokyo,
Japan). In each electron microscopy image (50/animal), the fol-
lowing structural changes were analyzed: (a) shedding surface
epithelium, (b) airway oedema, (c) eosinophil and neutrophil inﬁl-
tration, (d) subepithelial ﬁbrosis, (e) smooth muscle hypertrophy,
(f) myoﬁbroblast hyperplasia, (g) mucous cell hyperplasia and (i)
multinucleated cells (Antunes et al., 2010; Abreu et al., 2011a).
Pathologic ﬁndings were graded on a ﬁve-point semi-quantitative
severity-based scoring system, where 0 = normal lung parenchyma,
1 = changes in 1–25%, 2 = changes in 26–50%, 3 = changes in 51–75%,
and 4 = changes in 76–100% of examined tissue. Analysis was per-
formed by two  blinded pathologists.
2.6. Confocal microscopy
Fluorescent images of the basement membrane were obtained
using a confocal microscope (Leica Microsystems Ltd., Heidelberg,
Germany). Tissue sections were pretreated with PBS for 30 min  and
incubated overnight at room temperature in a humidiﬁed chamber
with a mouse antibody against type V collagen (1:50), followed
by double staining with ﬂuorescein and rhodamine (rhodamine-
conjugated goat anti-mouse IgG-R, dilution 1:40, Santa Cruz
Biotechnology, Santa Cruz, CA). For recipients of GFP marrow
transplants, 1 week after BMDMC  administration, frozen sections
were treated with 4′,6-diamidino-2-phenylindole dihydrochlo-
ride (DAPI)-supplemented mounting medium (Vectashield, Vector
Labs, Burlingame, CA), cover-slipped and examined for GFP expres-
sion by confocal microscopy. Background autoﬂuorescence was
determined through examination of 10 simultaneously prepared
negative control sections that were stained only with DAPI. Images
were processed and reconstructed using NIH Image software and
contrast and colour levels were adjusted in Adobe Photoshop 7.0.
The number of GFP+ cells per tissue area was determined by the
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Fig. 1. Schematic ﬂow chart (A) and timeline (B) of study design. C: Mice sensitized and challenged with saline; OVA: mice sensitized and challenged with ovalbumin; SAL:
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nalyzed on day 47.
oint-counting technique (Weibel, 1990; Araujo et al., 2010) across
0 random, non-coincident microscopic ﬁelds.
.7. Enzyme-linked immunosorbent assay (ELISA)
Levels of interleukin (IL)-4, IL-13, transforming growth factor
TGF)- and vascular endothelial growth factor (VEGF) in lung tis-
ue 24 h after the last challenge were evaluated by ELISA using
atched antibody pairs from PrepoTech and R&D Systems (Min-
eapolis, MN,  USA), according to manufacturer instructions. Results
re expressed in pg/ml.
.8. Statistical analysis
Data were tested for normality using the Kolmogorov–Smirnov
est with Lilliefors correction and the homogeneity of variances was
ssessed with the Levene median test. If both conditions were sat-
sﬁed, two-way ANOVA, followed by Tukey’s test when required,
as used for the comparison of differences among the groups. Non-
arametric data were analyzed using ANOVA on ranks followed by
ukey’s test. Parametric data were expressed as mean ± SEM, while
on-parametric data were expressed as median (interquartile
ange). All tests were performed using the SigmaPlot 11 software
ackage (SYSTAT, Chicago, IL, USA), and statistical signiﬁcance was
stablished as p < 0.05.
. Results
The pool of injected BMDMCs showed the following sub-
opulations: total lymphocyte (lower SSC, CD45+/CD11b−/
D29−/CD34− = 9.50%), T lymphocyte (lower SSC/CD45+/CD3+/
D34− = 5.4%), T helper lymphocyte (CD3+/CD4+/CD8−  = 1.7%),
 cytotoxic lymphocyte (CD3+/CD4−/CD8+ = 7.8%), B lym-
hocytes (CD19+ = 7.65%), monocytes (CD45+/CD29+/CD11b+
ow/CD34−/CD3− = 9.58%), haematopoietic progenitorsst challenge; IV: intravenous injection; IT: intratracheal instillation. All data were
(CD34+/CD45+ = 1.5%) and mesenchymal stem cells
(CD34−/CD45−/CD11b−  = 3.8%).
Because parameters of lung mechanics were similar regardless
of administration route in all control groups (C-SAL-IV and C-SAL-
IT, C-CELL-IV and C-CELL-IT) (data not shown), only the overall
results for C-SAL and C-CELL are presented. The OVA-SAL groups,
both IV and IT, had higher Est (26% and 29%), P1 (15% and 11%),
and P2 (49 and 64%) compared to C-SAL, respectively. Est, P1,
and P2 were lower in OVA-CELL than OVA-SAL regardless of the
route of administration (Fig. 2).
Lung morphometric examination demonstrated that the frac-
tion area of alveolar collapse (Figs. 3A and 4A), the number of
mononuclear cells and PMN  in lung tissue (Fig. 3B), contraction
index (Fig. 3C and 4B), and collagen ﬁbre content in the airway
and alveolar septa (Fig. 5) were higher in the OVA-SAL group than
in the C-SAL group. BMDMC  therapy reduced the fraction area of
alveolar collapse (Fig. 3A and 4A)  and PMN inﬁltration (Fig. 3B). It
also prevented changes in airway diameter (Fig. 3C and 4B) and
in the amount of collagen ﬁbre in the airway and alveolar septa
(Fig. 5).
Electron microscopy showed degenerative changes in ciliated
airway epithelial cells, inﬂammatory inﬁltration, myoﬁbroblast
and mucous cell hyperplasia, subepithelial ﬁbrosis with increased
thickness of basement membrane and smooth muscle hypertrophy
in OVA-SAL-IT and OVA-SAL-IV animals (Table 1, Fig. 6). Both IT and
IV BMDMC  instillation attenuated these ultrastructural changes.
Also, both IT and IV instillation of BMDMC  promoted Clara cell
proliferation and appearance of multinucleated cells and of undif-
ferentiated cells without a deﬁned phenotype (Table 1, Fig. 6).
In a separate set of experiments, BMDMCs isolated from GFP+
mice were used to compare the level of engraftment between
administration routes 1 week after cell administration. GFP+ cells
were detected in both OVA groups, but intratracheal instillation led
to higher pulmonary engraftment (4%) compared with intravenous
injection (1%). GFP+ cells were not detected in control lungs.
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Fig. 2. Lung static elastance (Est) (Panel A); resistive ((P1, grey bar), viscoelastic ((P2, white bar) and total pressures (Ptot = P1 + P2) (Panel B). C: mice sensitized and
challenged with saline; OVA: mice sensitized and challenged with ovalbumin; SAL: mice treated with saline; CELL: mice treated with BMDMCs (2 ×106) 24 h before the ﬁrst
challenge. IV: intravenous injection; IT: intratracheal instillation. *Signiﬁcantly different from C-SAL (p < 0.05). **Signiﬁcantly different from respective OVA-SAL (p < 0.05).
Fig. 3. Fraction area of normal (white bar) and collapsed alveoli (grey bar, Panel A), mononuclear (MN, white bar) and polymorphonuclear (PMN, grey bar) cells (Panel B),
bronchoconstriction index (Panel C). All values were computed in 10 random, non-coincident ﬁelds per mouse. C: mice sensitized and challenged with saline; OVA: mice
sensitized and challenged with ovalbumin; SAL: mice treated with saline; BMDMC: mice treated with BMDMCs (2 × 106) 24 h before the last challenge. IV: intravenous
injection; IT: intratracheal instillation. *Signiﬁcantly different from respective C-SAL (p < 0.05). **Signiﬁcantly different from respective OVA-SAL (p < 0.05).
S.C. Abreu et al. / Respiratory Physiology & Neurobiology 185 (2013) 615– 624 619
Fig. 4. Representative photomicrographs of lung parenchyma (upper panels) and airways (lower panels), haematoxylin–eosin stain. Collapsed areas in the lung parenchyma
and  a reduction in central airway diameter, as well as increased cell inﬁltration (arrows), are visible in OVA-SAL animals. C: mice sensitized and challenged with saline; OVA:
mice  sensitized and challenged with ovalbumin; SAL: mice treated with saline; CELL: mice treated with BMDMCs (2 × 106) 24 h before the ﬁrst challenge. IV: intravenous
injection; IT: intratracheal instillation. Original magniﬁcation: ×200 and ×400 (upper and lower panels, respectively). Bars = 100 m.
Fig. 5. Collagen ﬁbre content in the airways (Panel A) and lung parenchyma (Panel B). C: mice sensitized and challenged with saline; OVA: mice sensitized and challenged with
ovalbumin; SAL: mice treated with saline; CELL: mice treated with BMDMCs (2 × 106) 24 h before the ﬁrst challenge. IV: intravenous injection; IT: intratracheal instillation.
*Signiﬁcantly different from C-SAL (p < 0.05). **Signiﬁcantly different from respective OVA-SAL (p < 0.05).
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Table 1
Semi-quantitative electron microscopy analysis.
Groups C OVA
SAL CELL SAL CELL
IV IT IV IT IV IT IV IT
Shedding of surface epithelium 0 (0-0) 0 (0-0) 0 (0-0) 1 (0-1)* 2 (2-3)* 2 (1-4)* 1 (0-1)*,# 1 (0-2)*,#
Airway oedema 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 2 (2-3)* 3 (2-4)* 1 (1-2)*,# 1 (0-1)*,#
Eosinophil inﬁltration 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 3 (3-4)* 3 (2-4)* 1 (1-2)*,# 1 (1-2)*,#
Neutrophil inﬁltration 0 (0-0) 0 (0-0) 1 (0-1)* 1 (0-1)* 2 (1-3)* 2 (1-4)* 1 (0-1)*,# 1 (1-2)*,#
Disarrangement of ciliated epithelial cells 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 2 (1-3)* 2 (2-3)* 1 (1-2)*,# 1 (1-2)*,#
Subepithelial ﬁbrosis 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 2 (2-3)* 2 (2-3)* 1 (1-2)*,# 1 (1-2)*,#
Elastic ﬁbre fragmentation 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 2 (2-3)* 2 (2-3)* 1 (0-2)*,# 1 (0-1)*,#
Smooth muscle hypertrophy 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 2 (2-3)* 3 (2-4)* 1 (0-1)*,# 1 (1-2)*,#
Myoﬁbroblast hyperplasia 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-0) 3 (3-4)* 3 (3-4)* 1 (1-2)*,# 1 (1-2)*,#
Clara cell hyperplasia 0 (0-0) 0 (0-0) 1 (0-1)* 1 (0-1)* 0 (0-0) 0 (0-0) 1 (1-2)*,# 2 (1-3)*,#
Multinucleated cells 0 (0-0) 0 (0-0) 1 (0-1)* 1 (0-1)* 0 (0-0) 0 (0-0) 2 (2-4)*,# 2 (1-3)*,#
Pathologic ﬁndings were graded as: 0 = normal lung parenchyma, 1 = changes in 1–25%, 2 = 26–50%, 3 = 51–75%, and 4 = 76–100% of the examined tissue. C: mice sensitized
and  challenged with saline; OVA: mice sensitized and challenged with ovalbumin; SAL: mice treated with saline; BMDMC: mice treated with BMDMCs (2 × 106) 24 h before
the  last challenge. IV: intravenous injection; it: intratracheal instillation.
* Signiﬁcantly different from respective (IV or IT) C-SAL (p < 0.05).
# Signiﬁcantly different from respective (IV or IT) OVA-SAL (p < 0.05).
Fig. 6. Electron microscopy of lung parenchyma. C: mice sensitized and challenged with saline; OVA: mice sensitized and challenged with ovalbumin; SAL: mice treated
with  saline; CELL: mice treated with BMDMCs (2 × 106) 24 h before the ﬁrst challenge. IV: intravenous injection; IT: intratracheal instillation. Clara cells (Clara), mucous cells
(Muc),  ciliated cells (Cil), multinucleated cells (*), basal membrane (BM), basal membrane thickness (arrows) and smooth muscle hypertrophy (SM).
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Fig. 7. Levels of interleukin (IL)-4, IL-13, transforming growth factor (TGF)- in mouse lung tissue. C: mice sensitized and challenged with saline; OVA: mice sensitized
and  challenged with ovalbumin; SAL: mice treated with saline; CELL: mice treated with BMDMCs (2 × 106) 24 h before the ﬁrst challenge. IV: intravenous injection; IT:
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p  < 0.05).
Levels of IL-4, IL-13, TGF- and VEGF in lung tissue were higher
n the OVA-SAL group than in the C-SAL group. Intravenous and
ntratracheal BMDMC  administration yielded similar reductions in
he levels of these cytokines and growth factors (Fig. 7).
. Discussion
In the murine model of allergic asthma used in the present study,
arly BMDMC  therapy through the intravenous and intratracheal
outes resulted in similar beneﬁts, reducing alveolar collapse, bron-
hoconstriction, eosinophil inﬁltration, collagen ﬁbre content in
he airway and alveolar septa, airway oedema, and myoﬁbroblast
ypertrophy and hyperplasia, as well as improving airway epithe-
ial repair and lung mechanics. Since the higher BMDMC  pulmonary
ngraftment observed with intratracheal instillation compared to
ntravenous injection did not potentiate the beneﬁcial effects of
MDMC therapy, these beneﬁcial changes may  be attributed to the
bility of BMDMCs to modulate IL-4, IL-13, TGF- and VEGF levels
n lung tissue from a distant site.
In the present study, we used a model of allergic inﬂammation
reviously described by our group in BALB/c mice (Xisto et al., 2005;
urburan et al., 2007; Antunes et al., 2009). Nevertheless, C57BL/6
ice were used, because they serve as a background strain for GFP
ice (Abreu et al., 2011a)  and exhibit inﬂammatory (eosinophiliay different from C-SAL (p < 0.05). **Signiﬁcantly different from respective OVA-SAL
and Th2 pro-inﬂammatory cytokine increase) and ultrastructural
changes in the airway and lung parenchyma which closely mirror
human disease compared to other strains, even in the absence of
alum adjuvant (Yu et al., 2006; Antunes et al., 2009; Allen et al.,
2012). A recent study demonstrated that NLRP3 inﬂammasome
activation is essential in alum-free models of allergic asthma as
it leads to IL-1 production, a critical factor for the induction of Th2
inﬂammatory allergic response (Besnard et al., 2011). Even though
the use of alum adjuvant during the immunization phase of the
OVA model has been demonstrated to enhance the cardinal fea-
tures of allergic airway disease, this practice has been called into
question, since it is an artiﬁcial method of asthma induction with
major differences in relation to the pathogenesis of allergic disease
in humans.
Several recent studies have investigated the intravenous admin-
istration of mesenchymal stem cells in experimental models of
asthma, focusing on the beneﬁcial effects of these cells on lung
remodelling and inﬂammation (Bonﬁeld et al., 2010; Firinci et al.,
2011; Goodwin et al., 2011). However, MSC pose a series of
disadvantages, such as culture conditions detrimental to cell trans-
plantation and risk of contamination and immunologic reactions.
In light of these limitations, our group evaluated the effects of
intravenous BMDMC  administration in a model of allergic asthma
(Abreu et al., 2011a). BMDMCs can be administered easily and
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afely on the day of harvesting. They also express several genes
nvolved in inﬂammatory response and chemotaxis (Ohnishi et al.,
007), and are less costly than MSCs. Additionally, further studies
hould investigate whether the nature of BMDMCs as an heteroge-
eous mix  of progenitor and immune cells could induce beneﬁcial
ffects, with each cellular type playing a speciﬁc role. In that sce-
ario, the action and interaction between each cell type present
n the bone marrow mononuclear fraction would be essential to
chievement and potentiation of the functional effects of cell ther-
py (Mathieu et al., 2009; Lu et al., 2011). The present analysis is
ot sufﬁcient to distinguish which cell fraction in the BMDMC  sam-
le gave rise to the therapeutic effects observed. Determination
f which speciﬁc cell types are responsible for these features will
equire future experiments, such as transplant studies using cell
orters, a comparative study of bone marrow cell populations and
n vitro functional bioassays of BMDMCs.
Although intravenous administration of BMDMCs has been
ffective as a pre-treatment protocol for asthma, reducing inﬂam-
ation and remodelling and yielding better lung function (Abreu
t al., 2011a), we  investigated whether intratracheal instillation of
MDMCs, a more direct route to the lungs, would be more effec-
ive, delivering a higher number of cells (Bonios et al., 2011). This
ould translate in clinical practice into bronchoscopic delivery of
hese cells, a procedure that can be performed safely in asthmatic
atients following allergen challenge (Elston et al., 2004; Busse
t al., 2005). In order to identify homing of bone marrow cells in lung
arenchyma, GFP-positive cells derived from male mice (a reliable
arker of engrafted cells) were quantiﬁed. GFP-positive cells were
bserved in the OVA-CELL groups, but not in C-CELL lungs, sug-
esting that tissue damage is necessary to attract and retain these
ells even when they are intratracheally administered. As stated
lsewhere, the inﬂammatory process plays an essential role in cell
ecruitment to the injured area (Herzog et al., 2006). Nevertheless,
he source of signals responsible for mobilization and homing of
ndogenous and exogenous stem cells remains unclear. Stem cell
ecruitment varies according to the degree (Herzog et al., 2006) and
ype of tissue damage (Abe et al., 2004).
Lung accumulation of intravenously injected stem cells is pro-
ortional to the presence of adhesion molecules on the cell surface
nd to the size of the cell. Most cells in the bone marrow frac-
ion do not express major adhesion molecules, such as vascular cell
dhesion molecule-1 (VCAM-1), when binding to pulmonary vas-
ular endothelium. BMDMCs are also smaller compared to other
ell types, such as MSCs (Fischer et al., 2009). Therefore, BMDMCs
ass easily through the pulmonary capillaries and into the systemic
irculation when injected intravenously, reaching distal organs
ather than remaining in the lung tissue (Lassance et al., 2009).
e expected that intratracheal instillation would promote a more
arked pulmonary engraftment than that actually observed in the
resent study. However, cell trapping in the lungs was only evalu-
ted 1 week after BMDMC  administration, which may  explain the
ow degree of GFP-positive cell pulmonary engraftment: during
hese 7 days, a portion of the administered cells may  have been
ost due to immune rejection by the host, since our population of
MDMCs constitutes an allotransplant (Ortiz et al., 2003). Simulta-
eously, just as these cells can pass from the intravascular space to
he lungs, so can they pass from the lung tissue to the intravascu-
ar space, reaching the systemic circulation and being distributed
hroughout the body, reducing even further the number of GFP-
ositive cells in the lung parenchyma.
Even though intratracheal instillation yielded a higher num-
er of cells trapped in the lung parenchyma, suggesting that this
oute of administration could maximize cell delivery to the lung
nd directly reach the injury site, both administration routes led
o a decrease in collapsed areas and cell inﬁltration in the air-
ay and lung parenchyma, as well as a reduction in collagen ﬁbre Neurobiology 185 (2013) 615– 624
content, improving lung mechanics. Therefore, the beneﬁcial
effects of BMDMC  therapy observed in the present study may  be
associated with the ability of BMDMCs to modulate cytokine and
growth factor synthesis without being present at the site of injury
(Abreu et al., 2011b; Goodwin et al., 2011; Ratajczak et al., 2011).In
control animals, injection of BMDMCs led to an increase in PMN  lev-
els in lung tissue, with no functional effects. This increment may  be
associated with the presence of immune cells in the BMDMC  pool or
recruitment of these cells by chemoattraction (Araujo et al., 2010;
Prota et al., 2010; Abreu et al., 2011a,b; Maron-Gutierrez et al.,
2011; Cruz et al., 2012).
Complete regeneration of the airway epithelium is a com-
plex phenomenon that encompasses both epithelial wound repair
and differentiation (Knight et al., 2010). Regeneration implies two
components: epithelial stem/progenitor cells and factors able to
regulate this process. In asthma, the ability to restore the epithelial
barrier may  fail after repeated injury leads to airway remodelling
(Volckaert et al., 2011). Therefore, administration of BMDMCs may
potentiate airway epithelial cell repair. In this study, we observed
that BMDMCs, regardless of administration route, appeared to
repair airway ciliated epithelial cells associated with several fea-
tures of the regenerative process, such as proliferation of Clara cells
(airway progenitor cells) and the presence of multinucleated and
undifferentiated cells in lung parenchyma (Table 1). It has been
demonstrated that, after airway epithelial cell injury, Clara cells
are stimulated to undergo a transient epithelial-to-mesenchymal
transition (EMT) to initiate the repair process, promoting restora-
tion and function of the airway epithelium (Morimoto and Yatera,
2002). However, the precise mechanisms underlying cell restora-
tion remain unclear.BMDMC-derived soluble factors may  be the
main mechanism involved in the effective impact of BMDMC  ther-
apy on airway function and histology in asthma. Both OVA groups
in our study exhibited high levels of IL-4 and IL-13, important medi-
ators in the pathophysiology of asthmatic airway disease (Barlow
et al., 2012). Fibrocytes stimulated with IL-4 and IL-13 produce high
levels of collagen and non-collagen components of the extracellu-
lar matrix (Bellini et al., 2011), and the balance between levels of
these cytokines is related to recruitment of eosinophils to the lung
parenchyma (Rothenberg et al., 2011). Therefore, the reduction
in IL-4 and IL-13 promoted by BMDMC  therapy may  be associ-
ated with a decrease in the number of PMNs and collagen ﬁbre
content. Similarly, both BMDMC  administration routes were able
to reduce TGF- and VEGF levels, contributing to airway repair
and curtailing the remodelling process. In this context, TGF-,
the major mediator of EMT  (Alipio et al., 2011), may impair air-
way epithelial sheet migration over matrix-coated plates due to
enhancement of cell adhesion (Spurzem et al., 1993). It may also
play a key role in bronchial angiogenesis and vascular remodelling
in asthma via VEGF, an important angiogenic molecule (Willems-
Widyastuti et al., 2011). In this line, a recent study has reported that
VEGF receptor inhibition led to a signiﬁcant reduction in inﬂam-
mation and remodelling in experimental asthma (Lee et al., 2006).
Future studies should be conducted to address the role of pathways
involved in chemokine and growth factor production in the context
of BMDMC  therapy.
Our study has some limitations: (1) BMDMCs were injected 24 h
before the ﬁrst ovalbumin challenge, before the remodelling pro-
cess was established. Thus, more studies should be performed to
assess whether these routes of administration could promote simi-
lar effects in a remodelled airway; (2) we  cannot ascertain whether
the role of cytokines and growth factors is related to engraftment.
To clarify this issue, speciﬁc gene-deﬁcient animals should be used;
(3) even though the amount of GFP was  quantiﬁed in lung tissue,
we did not analyze whether these engrafted cells transdifferenti-
ated into any type of lung cell; and (4) we were unable to ascertain
the role of MSCs in our bone marrow fraction, even though they
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ccounted for approximately 4% of cells in this fraction (a propor-
ion higher than the average reported in the recent literature).
In conclusion, bone marrow-derived mononuclear cells were
ffective as a pre-treatment protocol in the murine model of aller-
ic asthma used herein, leading to a reduction in inﬂammatory and
emodelling processes and improving airway epithelial repair and
ung mechanics regardless of administration route. These improve-
ents were not affected by the higher pulmonary engraftment
bserved after intratracheal instillation compared to intravenous
dministration, suggesting an important role of BMDMCs in mod-
lating immune response.
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